Have a personal or library account? Click to login

Omega-3 supplementation in the treatment of polycystic ovary syndrome (PCOS) – a review of clinical trials and cohort

Open Access
|Feb 2022

References

  1. Ali FF, Rifaai RA. Preventive effect of omega-3 fatty acids in a rat model of stress-induced liver injury. J Cell Physiol 234, 11960–11968, 2019.10.1002/jcp.2784830536657
  2. Amini M, Bahmani F, Foroozanfard F, Vahedpoor Z, Ghaderi A, Taghizadeh M, Karbassizadeh H, Asemi Z. The effects of fish oil omega-3 fatty acid supplementation on mental health parameters and metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. J Psychosom Obstet Gynaecol 1–9, 2018.10.1080/0167482X.2018.150828230230402
  3. Arentz S, Smith CA, Abbott J, Bensoussan A. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. BMC Complement Altern Med 17, 500, 2017.10.1186/s12906-017-2011-x570214129178904
  4. Avila MAP, Bruno RV, Barbosa FC, Andrade FC, Silva ACO, Nardi AE. Polycystic ovary syndrome: implications of metabolic dysfunction. Rev Col Bras Cirur 41, 106–110, 2014.10.1590/S0100-6991201400020000624918723
  5. Baptiste CG, Batistta MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 122, 42–52, 2010.10.1016/j.jsbmb.2009.12.010384653620036327
  6. Barbalho SM, Bechara MD, Quesada KR, Goulart RA. Role of omega-3 fatty acids in the resolution of inflammatory processes. Medicina (Online) 44, 234–240, 2011.10.11606/issn.2176-7262.v44i3p234-240
  7. Becic T, Studenik C. Effects of omega-3 Supplementation on adipocytokines in prediabetes and type 2 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Metab J 42, 101–116, 2018.10.4093/dmj.2018.42.2.101591151329676540
  8. Buckley JD, Howe PRC. Long-chain omega-3 polyunsaturated fatty acids may be beneficial for reducing obesity – a review Nutrients 2, 1212–1230, 2010.10.3390/nu2121212325762622254005
  9. Cussons AJ, Watts GF, Mori TA, Stuckey BGA. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 94, 3842–3848, 2009.10.1210/jc.2009-087019622617
  10. de Sousa RML, Chen MBC, da Silva DSM, Dutra MB, Navarro PAAS, Neto JAF, Brito LMO. Metabolic profile in women of different body mass indices with polycystic ovary syndrome. Rev Bras Ginecol Obstet 35, 413–420, 2013.10.1590/S0100-7203201300090000624217570
  11. Ebrahimi FA, Samimi M, Foroozanfard F, Jamilian M, Akbari H, Rahmani E Ahmadi S, Taghizadeh M, Memarzadeh MR, Asemi Z. The effects of Omega-3 fatty acids and vitamin E co-supplementation on indices of insulin resistance and hormonal parameters in patients with polycystic ovary syndrome: a randomized, double-blind, Placebo-Controlled Trial. Exp Clin Endocrinol Diab 125, 353–359, 2017.10.1055/s-0042-11777328407657
  12. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 95, 048–1058, 2011.10.1016/j.fertnstert.2010.11.036307956521168133
  13. Foroozanfard F, Rafiei H, Samimi M, Gilasi HR, Gorjizadeh R, Heidar Z, Asemi Z. The effects of dietary approaches to stop hypertension diet on weight loss, anti-Müllerian hormone and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial. Clin Endocrinol 87, 51–58, 2017.10.1111/cen.1333328316072
  14. Gonzalez F, Sia CL, Shepard MK, Rote NS, Minium J. Hyperglycemia-induced oxidative stress is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome. Human Repr 27, 3560–3568, 2013.10.1093/humrep/des320350124222940766
  15. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7, 219–231, 2011.10.1038/nrendo.2010.21721263450
  16. Hajishafiee M, Askari G, Iranj B, Ghiasvand R, Bellissimo N, Totosy de Zepetnek J and Salehi-Abargouei A. The effect of n-3 polyunsaturated fatty acid supplementation on androgen status in patients with polycystic ovary syndrome: A systematic review and meta-analysis of clinical trials. Horm Met Res 48, 281–289, 2016.10.1055/s-0042-10528827077458
  17. Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. A case–control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Repr Health 12, 7, 2015.10.1186/1742-4755-12-7441724625595199
  18. Jamilian M, Shojaei A, Samimi M, Ebrahimi FA, Aghadavod E, Karamali M, Taghizadeh M, Jamilian H, Alaeinasab S, Jafarnejad S, Asemi Z. The effects of omega-3 and vitamin E co-supplementation on parameters of mental health and gene expression related to insulin and inflammation in subjects with polycystic ovary syndrome. J Affect Disord 229, 41–47, 2018.10.1016/j.jad.2017.12.04929306057
  19. Karakas SE, Perroud B, Kind T, Palazoglu M, Fiehn O. Changes in plasma metabolites and glucose homeostasis during omega-3 polyunsaturated fatty acid supplementation in women with polycystic ovary syndrome. BBA Clin 5, 179–185, 2016.10.1016/j.bbacli.2016.04.003485716027182493
  20. Khani B, Mardanian F, Fesharaki SJ. Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome. J Res Med Sci 22, 64, 2017.10.4103/jrms.JRMS_644_16546159428616051
  21. Lee MW, Park JK, Hong JW, et al. Beneficial effects of omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy. Diab Metab J 37, 207–211, 2013.10.4093/dmj.2013.37.3.207368901823807924
  22. Li L, Zhong Y, Zhang H, Yu H, Huang Y, Li Z, Chen G, Hua X. Association between oral contraceptive use as a risk factor and triple-negative breast cancer: A systematic review and meta-analysis. Mol Clin Oncol 7, 76–80, 2017.10.3892/mco.2017.1259549267128685080
  23. Mejia-Montilla J, Reyna-Villasmil E, Domínguez-Brito L, Naranjo-Rodríguez C, Noriega-Verdugoc D, Padilla-Samaniego M, Vargas-Olalla V. Suplementacion de acidos grasos omega-3 y adiponectina plasmatica en mu-jeres con sindrome de ovarios poliquisticos. Endocrinol Diabetes Nutr 65, 192–199, 2018.10.1016/j.endinu.2017.12.01029452758
  24. Mirmasoumi G, Fazilati M, Foroozanfard F, Vahedpoor Z, Mahmoodi S, Taghizadeh M, Esfeh NK, Mohseni M, Karbassizadeh H, Asemi Z. The Effects of flaxseed oil omega-3 fatty acids supplementation on metabolic status of patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Exp Clin Endocrinol Diab 126, 222–228, 2018.10.1055/a-1736-9017
  25. Mohammad-Alizadeh-Charandabi S, Mirghafourvand M, Froghy L, Javadzadeh Y, Razmaraii N. The effect of multivitamin supplements on continuation rate and side effects of combined oral contraceptives: A randomised controlled trial. Eur J Contracep Reprod Health Care 20, 361–371, 2015.10.3109/13625187.2015.101011525676163
  26. Mohammadi E, Rafraf M. Benefits of omega-3 fatty acids supplementation on serum paraoxonase 1 activity and lipids ratios in polycystic ovary syndrome. Health Promot Perspect 2, 197–204, 2012.
  27. Mohammadi E, Rafraf M, Farzadi L, Asghari-Jafarabadi M, Sabour S. Effects of omega-3 fatty acids supplementation on serum adiponectin levels and some metabolic risk factors in women with polycystic ovary syndrome. APJCN 21, 511–518, 2012.
  28. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 92, 1966–1982, 2009.10.1016/j.fertnstert.2008.09.01819062007
  29. Rafraf M, Mohammadi E, Asghari-Jafarabadi M, Farzadi L. Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome. JACN 31, 361–368, 2012.10.1080/07315724.2012.1072044323529993
  30. Nadjarzadeh A, Dehghani-Firouzabadi R, Daneshbodi H, Lotfi MH, Vaziri N, Mozaffari-Khosravi H. Effect of Omega-3 supplementation on Visfatin, adiponectin, and anthropometric indices in women with polycystic ovarian syndrome. J Reprod Infertil 16, 212–220, 2015.
  31. Najafi H, Changizi-ashtiyani S, Najafi M. Antioxidant activity of omega-3 derivatives and their elivery via nanocages and nanocones: DFT and experimental in vivo investigation. J Mol Model 23, 326, 2017.10.1007/s00894-017-3504-829080914
  32. Nybacka A, Carlstrom K, Stahle A, Nyren S, Hellstrom PM, Hirschberg AL. Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in over-weight women with polycystic ovary syndrome. Fertil Steril 96, 1508–1513, 2011.10.1016/j.fertnstert.2011.09.00621962963
  33. Oner G, Muderris II. Efficacy of omega-3 in the treatment of polycystic ovary syndrome. J Obstetr Gynecol 33, 289–291, 2013.10.3109/01443615.2012.75136523550861
  34. Phelan N, O’Connor A, Tun TK, Correia N, Boran G, Roche HM, Gibney J. Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial. JACN 93, 652–662, 2011.10.3945/ajcn.110.00553821270384
  35. Palmery M, Saraceno A, Vaiarell A, Carlomagno G. Oral contraceptives and changes in nutritional requirements. Eur Rev Med Pharmacol Sci 17, 1804–1813, 2013.
  36. Rafraf M, Mohammadi E, Asghari-Jafarabadi M, Farzadi L. Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome. JACN 31, 361–368, 2012.10.1080/07315724.2012.1072044323529993
  37. Rahmani E, Samimi M, Ebrahimi FA, Foroozanfard F, Ahmadi S, Rahimi M, Jamilian M, Aghadavod E, Bahmani F, Taghizadeh M, Memarzadeh MR, Asemi Z. The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein (a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome. Mol Cell Endocrinol 439, 247–255, 2016.10.1016/j.mce.2016.09.00827619403
  38. Rahmani E, Jamilian M, Dadpour B, Nezami Z, Vahedpoor Z, Mahmoodi S Aghadavod E, Taghizadeh M, Beiki Hassan A and Asemi Z. The effects of fish oil on gene expression in patients with polycystic ovary syndrome. EJCI 48, e12893, 2018.10.1111/eci.1289329359480
  39. Sadeghi A, Djafarian K, Mohammadi H, Shab-Bidar S. Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials. Diabetes Metab Syndr: Clin Res Rev 11, 157–162, 2017.
  40. Sadeghi F, Alavi-Naeini A, Mardanian F, Ghazvini MR, Mahaki B. Omega-3 and vitamin E co-supplementation can improve antioxidant markers in obese/overweight women with polycystic ovary syndrome. Int J Vit Nutr Res 90, 477–483, 2020.10.1024/0300-9831/a00058830961460
  41. Silva RC, Pardini DP, Kater CE. Polycystic ovary syndrome, metabolic syndrome, cardiovascular risk and the role of insulin sensitizing agents. Braz Arq Endocrinol Metabol 50, 281–290, 2006.
  42. Silva DEA. Prevalence of metabolic disorders in polycystic ovarian syndrome. RBONE-Rev Bras Obes Nutr Emagr 7, 2, 2013. (Abstract)
  43. Stegeman BH, Bastos M, Rosendaal FR, Vlieg AVH, Helmerhorst FM, Stijnen T, Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 347, f5298, 2013.10.1136/bmj.f5298377167724030561
  44. Talari HR, Poladchang S, Hamidian Y, Samimi M, Gilasi HR, Ebrahimi FA, Asemi Z. The effects of omega-3 and vitamin E co-supplementation on carotid intima-media thickness and inflammatory factors in patients with polycystic ovary syndrome. OMJ 33, 473–479, 2018.10.5001/omj.2018.88620642830410689
  45. Thota RN, Ferguson JJA, Abbott KA, Dias CB, Garg ML. Science behind the cardio-metabolic benefits of omega-3 polyunsaturated fatty acids: Biochemical effects vs. clinical outcomes. Food Funct 9, 3576–3596, 2018.10.1039/C8FO00348C
  46. Unluhizarci K, Kaltsas G, Kelestimur F. Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism. Eur J Clin Invest 42, 86–94, 2012.10.1111/j.1365-2362.2011.02550.x21623779
  47. Vargas ML, Almario RU, Buchan W, Kim K, Karakas SE. Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome. Metabolism 60, 1711–1718, 2011.10.1016/j.metabol.2011.04.007321088421640360
  48. Yang K, Zeng L, Bao T, Ge J. Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. Repr Biol Endocrinol 16, 27, 2018.10.1186/s12958-018-0346-x587091129580250
  49. Yao K, Bian C, Zhao X. Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy. Exp Ther Med 14, 1271–1276, 2017.10.3892/etm.2017.4642552611628810587
DOI: https://doi.org/10.2478/enr-2022-0008 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668
Language: English
Page range: 66 - 79
Published on: Feb 18, 2022
Published by: Slovak Academy of Sciences, Mathematical Institute
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year

© 2022 Vitoria Melo, Thomas Silva, Thaissa Silva, Juliana Freitas, Joselita Sacramento, Mirian Vazquez, Edilene Araujo, published by Slovak Academy of Sciences, Mathematical Institute
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.